3
Announcements
Trials
Browse
Landscape
Status
Completed
10
Unknown
2
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
6
Depression
4
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Anxiety Disorders
2
Urologic Diseases
1
Treatment Adherence and Compliance
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Sarcoma
1
Radiation Fibrosis Syndrome
1
Pyloric Stenosis, Hypertrophic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Hemorrhage
1
Peripheral Lung Tumor
1
Patient Acceptance of Health Care
1
Obesity
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
49
Carboplatin
44
Magnetic Resonance Spectroscopy
40
Specimen Handling
39
Pemetrexed
34
Cisplatin
25
Blood Specimen Collection
25
durvalumab
17
Paclitaxel
16
osimertinib
15
Radiotherapy
15
Radiosurgery
15
Bevacizumab
15
Gemcitabine
14
atezolizumab
13
Nivolumab
13
Biopsy
13
Drug Therapy
12
Standard of Care
10
Practice Guidelines as Topic
10
Immunoglobulin G
10
Docetaxel
10
130-nm albumin-bound paclitaxel
10
X-Rays
9
Taxes
9
Educational Status
9
Disulfides
9
tislelizumab
8
Etoposide
8
Cetuximab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lung Neoplasms
×
Therapeutics
×
Clear all
NCT03647098
2025-02-14
Soul
Hunan Province Tumor Hospital
Recruiting
20,000 enrolled